High rates of failure, exorbitant costs, and the sluggish pace of new drug discovery and
development have led to a growing interest in repurposing “old” drugs to treat both common …

Important breakthroughs in medical treatments have improved outcomes for patients
suffering from several types of cancer. However, many oncological treatments approved by …

Increasing cancer drug prices present global challenges to treatment access and cancer
outcomes. Substantial variability exists in drug pricing across countries. In countries without …

Objective To characterize the therapeutic value of new drugs approved by the US Food and
Drug Administration (FDA) and European Medicines Agency (EMA) and the association …

Importance The high cost of cancer medicines is a public health challenge. Policy makers in
the US and Europe are debating reforms to drug pricing that would cover both the prices of …

Background Over the past decades, the therapeutic landscape has markedly changed for
patients with metastatic solid cancer, yet few studies have evaluated its effect on population …

According to statistics, in the 185 countries' 36 types of cancer, the morbidity and mortality of
lung cancer take the first place, and non-small cell lung cancer (NSCLC) accounts for 85 …

In 2016, the then US President Barack Obama announced the Cancer Moonshot with a view
to making 10 years' worth of progress in cancer prevention, diagnosis and treatment in only …

Objective To analyze the therapeutic value of supplemental indications compared with first
indications for drugs approved in the US and Europe. Design Retrospective cohort study …

Importance Drug companies frequently claim that high prices are needed to recoup
spending on research and development. If high research and development costs justified …